Israel’s Yissum Invests in Avraham Pharmaceuticals

Investment gives Yissum, the university research development company of Hebrew University, a 30% holding share in company

Avraham Pharmaceuticals is based in Israel, and is working in the Alzheimer and other cognitive disease drug delivery and treatment processes. In this latest finance round totaling $3 Million, Yissum was joined by several investors, including Pontifax, TRDF, and Clal Biotechnology Industries. The venture funding will be used to complete two Phase II- clinical trials of Avraham’s ladostigil, a novel molecule developed to both treat cognitive impairment diseases, including Alzheimer's, but also lessen the psychological symptoms of memory loss, such as depression and anxiety. Ladostigil was exclusively licensed to Avraham Pharmaceuticals by Yissum and by the Technion Research and Development Foundation Ltd. (TRDF).

TechConnect News Note: Yissum has presented IPs from their portfolio at several TechConnect Summit events.

↑ Back to TechConnect News™

Event Spotlights

DITAC
Austin, TX, December 1-3, 2015
DES
Austin, TX, December 1-3, 2015
 

Annual Meeting

TechConnect World 2015
Washington, DC, May 22-25, 2016